Evidence map›Paper›PMID 40168319›Full record

ArticleACS infectious diseases2025

Toward a Bactericidal Oral Drug Combination for the Treatment of

Jickky Palmae Sarathy, Min Xie, Chui Fann Wong, Dereje A Negatu, Suyapa Rodriguez, Matthew D Zimmerman, Diana C Jimenez, Ilham M Alshiraihi, Mercedes Gonzalez-Juarrero, Véronique Dartois and 1 more

Abstract read
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Journal of bacteriology · 2026
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jickky Palmae SarathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Min XieCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Chui Fann WongCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Dereje A NegatuCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Suyapa RodriguezCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Matthew D ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.
Diana C JimenezMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Ilham M AlshiraihiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, United States.ORCID 0000-0002-4045-2365
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.ORCID 0000-0001-9470-5009
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey 07110, United States.ORCID 0000-0002-9604-9452

Funding

Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI PERLIN, DAVID S · 2019 to 2023
$33.9M
Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0M
Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung diseaseR01AI177342 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Courtney C Aldrich, Thomas Dick · 2023 to 2026
$3.4M
Shorter and more effective oral regimens for M. abscessus pulmonary diseaseR01AI184502 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Thomas Dick · 2025 to 2026
$1.8M
NIAID NIH HHS R01 AI132374NIAID NIH HHS R01 AI177342NIAID NIH HHS R01 AI184502NIAID NIH HHS U19 AI142731
6 · The paper itself

Abstract

Treatment of

Indexed as

Anti-Bacterial AgentsLung DiseasesMycobacterium abscessusMycobacterium Infections, NontuberculousAdministration, OralAnimalsAzabicyclo Compoundsbeta-LactamsDrug CombinationsDrug Therapy, CombinationFemaleFluoroquinolonesHumansMiceMicrobial Sensitivity TestsMoxifloxacinAnti-Bacterial AgentsavibactamAzabicyclo Compoundsbeta-LactamsDrug CombinationsFluoroquinolonesfropenemMoxifloxacinRifabutinbacterial cell deathbactericidal antibioticsdrug combinationsnontuberculous mycobacteriaNTMpost antibiotic effect

Identifiers

PMID40168319
PMCPMC11997990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.